Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative To Improve Quality Of Care Through Identification, Dissemination, And Implementation Of Best Practices For The Diagnosis And Management Of Recurrent Pericarditis

– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis –

 

– American Heart Association to work with champions at 15 healthcare sites to implement initiative activities and improve care quality –

HAMILTON, Bermuda, June 17, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced its sponsorship of the American Heart Association's new Addressing Recurrent Pericarditis initiative, a multi-faceted effort to improve quality of care through identification, dissemination, and implementation of best practices for the diagnosis and management of recurrent pericarditis.